My guest for this interview is Rebecca Matthews, Chief Clinical Operations Officer at Multidisciplinary Association for Psychedelic Studies (MAPS) Public Benefit Corporation. In this interview, Rebecca shares with us what it takes to conduct clinical trials investigating the use of MDMA, a psychedelic drug, in conjunction with psychotherapy to treat patients with post traumatic stress disorder (PTSD). PTSD can occur after a person experiences a significant trauma, like a sexual assault, severe physical assault, significant threat to life arising from a hate crime, natural disaster, war, or accident. It affects people of all races, ages, and backgrounds. As you'll hear from Rebecca shortly, the clinical data from the recent clinical trial looks extremely promising. This interview will leave you with excellent insights on differences and challenges of conducting research with psychedelic drugs including site selection, patient recruitment, clinical trial design considerations and more. I am beyond excited to discuss this important topic of psychedelic research on the podcast. Please join me in welcoming Rebecca Matthews on the Clinical Trial Podcast. Enjoy! Podcast Sponsor This interview you brought you Florence Healthcare. Transform your Clinical Trials with the #1 Platform for Electronic Document Workflows and Remote Site Access. Learn how Florence Healthcare helps over 7,200 research sites, sponsors, and CROs across 27 countries take their day back from paper.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related